D311, d107
Phase 1
Chong Kun Dang PharmaceuticalD311, d107 is one of 32 therapeutic programs targeting Hypertension. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Baxfendy
AstraZenecaPhase 3
Minocycline /d
UUniversity of Florida
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for D311, d107. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]